Gu Yulong, Doughty Robert N, Freedman Ben, Kennelly John, Warren Jim, Harwood Matire, Hulme Richard, Paltridge Chris, Teh Ruth, Rolleston Anna, Walker Natalie
School of Health Sciences, Stockton University, Galloway, New Jersey, USA.
Department of Medicine, The University of Auckland, Auckland, New Zealand.
Intern Med J. 2018 Mar;48(3):301-309. doi: 10.1111/imj.13648.
Atrial fibrillation (AF) is a major risk factor for ischaemic stroke and cardiovascular events. In New Zealand (NZ), Māori (indigenous New Zealanders) and Pacific people experience higher rates of AF compared with non-Māori/non-Pacific people.
To describe a primary care population with AF in NZ. Stroke risk and medication adherence according to ethnicity are also detailed.
Electronic medical records for adults (≥20 years, n = 135 840, including 19 918 Māori and 43 634 Pacific people) enrolled at 37 NZ general practices were analysed for AF diagnosis and associated medication prescription information.
The overall prevalence of non-valvular AF (NVAF) in this population was 1.3% (1769), and increased with age (4.4% in people ≥55 years). Māori aged ≥55 years were more likely to be diagnosed with NVAF (7.3%) than Pacific (4.0%) and non-Māori/non-Pacific people (4.1%, P < 0.001). Māori and Pacific NVAF patients were diagnosed with AF 10 years earlier than non-Māori/non-Pacific patients (median age of diagnosis: Māori = 60 years, Pacific = 61 years, non-Māori/non-Pacific = 71 years, P < 0.001). Overall, 67% of NVAF patients were at high risk for stroke (CHA DS -VASc ≥ 2) at the time of AF diagnosis. Almost half (48%) of Māori and Pacific NVAF patients aged <65 years were at high risk for stroke, compared with 22% of non-Māori/non-Pacific (P < 0.001). Irrespective of ethnic group, adherence to AF medication was suboptimal in those NVAF patients with a high risk of stroke or with stroke history.
AF screening and stroke thromboprophylaxis in Māori and Pacific people could start below the age of 65 years in NZ.
心房颤动(AF)是缺血性中风和心血管事件的主要危险因素。在新西兰(NZ),与非毛利人/非太平洋岛民相比,毛利人(新西兰原住民)和太平洋岛民患AF的比例更高。
描述新西兰患有AF的初级保健人群。还详细介绍了按种族划分的中风风险和药物依从性。
分析了新西兰37家全科诊所登记的成年人(≥20岁,n = 135840,包括19918名毛利人和43634名太平洋岛民)的电子病历,以获取AF诊断和相关药物处方信息。
该人群中非瓣膜性AF(NVAF)的总体患病率为1.3%(1769例),且随年龄增长而增加(≥55岁人群中为4.4%)。≥55岁的毛利人被诊断为NVAF的可能性(7.3%)高于太平洋岛民(4.0%)和非毛利人/非太平洋岛民(4.1%,P < 0.001)。毛利人和太平洋岛民的NVAF患者被诊断出AF的时间比非毛利人/非太平洋岛民患者早10年(诊断中位年龄:毛利人 = 60岁,太平洋岛民 = 61岁,非毛利人/非太平洋岛民 = 71岁,P < 0.001)。总体而言,67%的NVAF患者在AF诊断时处于中风高危状态(CHA₂DS₂-VASc≥2)。年龄<65岁的毛利人和太平洋岛民NVAF患者中近一半(48%)处于中风高危状态,而非毛利人/非太平洋岛民为22%(P < 0.001)。无论种族如何,在那些有中风高危风险或有中风病史的NVAF患者中,AF药物的依从性都不理想。
在新西兰,毛利人和太平洋岛民的AF筛查和中风血栓预防可以在65岁以下开始。